Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?
|
|
- Damon Douglas O’Neal’
- 6 years ago
- Views:
Transcription
1 MYELOPROLIFERATIVE NEOPLASMS:ACLINICAL UPDATE Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes? Eric Padron 1 1 Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL The myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) lie at the interphase of phenotypically opposing bone marrow malignancies. They are characterized by concomitant features of bone marrow failure and myeloproliferation and are generally associated with a poor prognosis. Although much is unknown with respect to the clinical course and molecular biology of MDS/MPNs, emerging research is beginning to uncover the key defining characteristics of this designation. In this review, we will discuss the features of MDS/MPN diseases that unify there clinical and molecular course and those that define distinct disease entities. We will discuss advances in genetics and MDS/MPN modeling, as well as translational discoveries that are anticipated to inform the diagnosis, prognostication, and treatment of MDS/MPNs in the near future. The myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) are a unique group of myeloid malignancies that converge on a paradoxical bone marrow phenotype hallmarked by myeloid lineage subset proliferation in the context of bone marrow dysplasia and ineffective hematopoiesis. 1 The members of this World Health Organization (WHO) designation include chronic myelomonocytic leukemia (CMML), atypical chronic myelomoncytic leukemia (acml), juvenile myelomonocytic leukemia (JMML), and MDS/ MPN unclassifiable (MDS/MPN-U). 2 Refractory anemia with ringed sideroblasts and thrombocytosis (RARS-T) remains a provisional entity under consideration for formal entry into the MDS/MPN designation by the WHO. The underlying pathogenesis responsible for, or at least tolerant of, the bone marrow paradox is not clear nor is the molecular convergence point that biologically defines the MDS/MPN category as a whole. What is known is that the bone marrow phenotype of MDS/MPNs consists of increased cellular programmed cell death, resultant dysplasia, and cytopenias along with concomitant myeloid subset skewing and proliferation. 3 This phenomenon is seen in MDS and MPNs, respectively, but not in combination. The annotation of recurrent genetic mutations in MDS/MPNs has led to significant insights into the dysregulated pathways that could be responsible for the combined phenotype (Table 1). 4-7 As could be expected, mutations in signaling genes are recurrently mutated in MDS/MPNs such as CBL, JAK2, N- and K-RAS, and CSF3R in the background of MDS-like mutations, such as those of the spliceosome complex. 4,7,8 These observations suggests that co-mutation of genes involved in dysplasia and bone marrow failure along with those of cytokine receptor signaling may, in part, explain the dual MDS/ MPN phenotype. One example of comutation driving a MDS/MPN phenotype is that of RARS-T. A genetic hallmark of this MDS/ MPN subtype is the comutation of SF3B1, a genetic determinant of ringed sideroblasts, and JAK2. 9 This mutational combination occurs in approximately 40%-50% of all RARS-T but does not occur with the refractory anemia and ringed sideroblast (RARS) subtype of MDS or essential thrombocytosis in which SF3B1 and JAK2 mutations are common in isolation, respectively. 10 Further, anecdotal reports have demonstrated that acquisition of JAK2 mutation is associated with a change from RARS to that of a RARS-T phenotype. This collectively suggests that these driver mutations are critical to the unique combinatory phenotype of RARS-T. However, this mutational combination is not exclusively seen in MDS/MPN and not every MDS/MPN patient harbors a mutation in signaling related genes. Further, combinations of mutations that are not intuitively associated with myeloproliferation, such as that of SRSF2 and TET2 are highly associated with CMML. 11 JMML, a monocytic leukemia seen in children 3 years of age, is associated with mutations that exclusively alter the RAS pathway without recurrent mutations in epigenetic or spliceosome genes. 4 This suggests that, although some genetic combinations seen in MDS/ MPNs are likely to explain bone marrow behavior, genetic alterations are unlikely to explain the major convergence point of MDS/MPNs in isolation. Deeper insights into the downstream consequences secondary to mutational combinations and their interaction with the bone marrow microenvironment will be critical to understanding the unique behavior of this class of malignancies. Despite the phenotypic similarities in bone marrow behavior among MDS/MPNs, profound differences in the population affected, natural history, and clinical course exist. JMML is an uncommon myeloid malignancy of early life (age 3 yrs) with a disproportionate male preponderance. It is a heterogeneous clinical entity in that some patients, particularly those with Noonan syndrome, have spontaneous resolution of their disease despite identification of clonal hematopoiesis, whereas others can have a fulminant course. 12 The natural history of CMML is also highly heterogeneous across patient subgroups with a median overall survival (OS) of 34 months and leukemic transformation rates of 15%-20% likely secondary to its genetic heterogeneity compared to JMML. 13 Unlike JMML, CMML is a disease of the elderly with a median age of approximately 70 years and spontaneous remissions have not been reported. Atypical CML is a rare MDS/MPN whose incidence is estimated at Conflict-of-interest disclosure: The author declares no competing financial interests. Off-label drug use: Ruxolitinib for the treatment of CMML and acml. Hematology
2 Table 1. Frequencies of recurrent genetic mutations in MDS/MPNs CMML JMML acml MDS/MPN-U RARS-T % ASXL ? 15 CALR CBL ? 4 CSF3R 0 0 Variable 0 0 DNMT3A 2 0?? 15 ETV6 1 0?? 3 EZH2 5 0? 10? IDH1/2 6 0??? JAK JAK3 N/A 12??? K/N ? RAS NF1 1 13??? PTPN ??? RUNX1 15 0? 14? SETBP SF3B1 6 0?? 93 SRSF2 46 0?? 7 TET2 58 0?? 25 TP53 1 0??? U2AF1 5 0?? 5 ZRSF2 8 0?? 3 Distinction between 0 and? is that data exists that mutation has been profiled or not, respectively. 1% of that of typical, BCR-ABL1 positive CML. 14 The natural history is not well established in the literature but the overall prognosis is thought to be poor. RARS-T is a comparably more indolent disease of the elderly with median survivals estimated as high as 7 years. 10 The WHO diagnostic criteria of MDS/MPNs are summarized in Table 2. In general, the respective MDS/MPN diseases are identified by the type of myeloid subset, which predominates in the peripheral blood. For example CMML and JMML are characterized by a unique expansion of peripheral blood monocytes, whereas acml is associated with highly dysplastic granulocyte predominance. 1,12 RARS-T is hallmarked by thrombocytosis while MDS/ MPN-U has no clear association with a specific myeloid subset but instead is identified by clinical and/or pathologic manifestations of myeloproliferation and bone marrow failure. 15 In this review, we will highlight the emerging preclinical tools, clinical data, and therapeutic strategies that are anticipated to increase our understanding of these unique diseases and improve their clinical management. Bedside to bench or bench to bedside: MDS/MPN preclinical models Models derived from human MDS/MPN genetic discoveries Large-scale human genome sequencing in MDS/MPNs has led to advances in the annotation of recurrent genetic mutations that are postulated to be sufficient to induce the phenotype in which they were discovered. This, in turn, has led to the development of several monogeneic murine models that recapitulate a bone marrow failure syndrome or the MDS/MPN phenotype. For example, TET2 somatic loss of function mutations occur at frequencies approaching 50% in CMML and have be modeled by deleting TET2 in several murine systems. 16 Interestingly, despite the wide-spread occurrence of TET2 mutations across myeloid malignancy, TET2 ( / ) murine Table 2. WHO defined diagnostic criteria for MDS/MPN classification CMML acml JMML MDS/MPN-U Peripheral blood monocytosis Features of one MDS category and Diagnostic criteria Persistent peripheral blood WBC with increased and monocytosis dysplastic neutrophils No BCR-ABL1 or PDGFR fusion gene No BCR-ABL1 or PDGFR fusion gene prominent myeloproliferative features and No BCR-ABL1 or PDGFR fusion gene no preceding history of MPN or MDS and no BCR-ABL1 or PDGFR fusion and no isolated del(5q), chr 3 inversion or Fewer than 20% blasts in the blood and bone marrow 20% blasts in the blood and bone marrow 20% blasts in the blood and bone marrow Minimal absolute basophilia Two of the following must be present: features of mixed MDS and MPN and cannot be assigned MDS, MPN, or MDS/MPN category Dysplasia in one more lineages, if no dysplasia then: No or minimal monocytosis Hemoglobin F increase Immature granulocytes in peripheral blood Hypercellular BM with granulocyte dysplasia an aquired clonal cytogenetic or genetic abnormality the monocytosis is has persisted for 3 months and WBC greater than 10x10 9 /L Neutrophil precursors 10% of peripheral blood WBC all causes of monocytosis have been excluded Clonal chromosome abnormality GM-CSF hypersentivity of myeloid progenitors in vitro 350 American Society of Hematology
3 models strikingly phenocopy proliferative CMML with features that include splenomegaly, monocytosis, and dysplasia. 17,18 This is particularly notable given recent data demonstrating that early clonal dominance of TET2 mutations in human samples may be a CMML-specific feature suggesting that TET2 dosage may be a determinant of an MDS/MPN phenotype. 19 Another example of a monogeneic MDS/MPN model informed by human genetics is ASXL1. ASXL1 frame shift mutations occur at comparable frequency to TET2 mutations and are universally adversely prognostic. 20 In contrast to TET2, murine models deleting this gene [ASXL1 ( / )] result in a bone marrow failure syndrome akin to MDS with concomitant genome wide alterations in H3K27me3 and H3K4me3 marks. 21 SRSF2 conditional knock-in murine models have also been reported to induce a bone marrow failure syndrome and not MDS/MPN despite an incidence of SRSF2 mutations approaching 45%. 22 NRAS, SHP2, NF1, and CBL mutations, which predominantly occur in JMML and CMML, have been modeled by several investigators and demonstrate a myelomonocytic phenotype similar to the above diseases Interestingly, these murine models display profound GM-CSF-specific hypersensitivity which is a hallmark feature of JMML and CMML. Lastly, CSF3R murine models, which have been demonstrated to be mutated in acml and chronic neutrophilic leukemia, have been generated. These mice indeed phenocopy an acml- like disease and importantly respond to treatment with JAK inhibitors, an observation that was identified in in vitro human studies. 27 Collectively these models are sufficient to induce a bone marrow disease that, in some cases, mimics MDS/MPN but suggests that complex interactions of gene mutations and perhaps microenvironmental influences are likely to explain genotype/ phenotype relationships. It is anticipated that these models and their combinations will serve as excellent preclinical tools for therapeutic testing. Models derived from preclinical observation In addition to mice generated from observations from human disease, MDS/MPN phenotypes have been seen in murine models that were unexpected based on human genetic profiling. One interesting example is knockout of XIST. XIST is a well-described long-noncoding RNA (lncrnas) that is critical for X chromosome inactivation. However, deletion of this non-coding RNA was sufficient to induce a highly penetrant and aggressive MDS/MPN in female mice. 28 Hematopoeitic stem cells (HSCs) from this model demonstrated aberrant maturation and were of hematopoietic origin suggesting a protective effect of XIST. Another interesting model was that of NOTCH deficiency. NOTCH signaling suppression in murine models resulted in myelomonocytic predominance and a CMML-like disease. Further, mutations in NOTCH were identified, although rarely, in patient CMML samples suggesting human disease relevance. 29 Other MDS/MPN models have been generated that were a result of CREBBP depletion, NR4A depletion, and others which have increased our understanding with respect to pathways whose dysregulation can lead to the disease phenotype. 30,31 Diagnostic challenges and updates in MDS/MPNs MDS/MPN by definition includes phenotypic properties of both MDS and MPNs, respectively. Thus, a critical diagnostic decision lies in determining that your patient does not fall in either of the above categories and is instead an overlap syndrome. The criteria to make these decisions in many cases are not straightforward. For example, patients may meet criteria for MDS but have pathologic evidence of overlap with megakaryocytic proliferation and clustering while having no clinical or peripheral evidence of proliferation. Should this patient be classified as MDS/MPN? Additionally, a patient may meet criteria for CMML but have subtle dysplasia and significant fibrosis in the bone marrow by reticulin staining. 32 Should this patient be classified as myelofibrosis? Although diagnostic dilemmas occur at the interphase of diseases across cancer, it is particularly relevant to reflect on this in MDS/MPNs because its definition relegates the entire designation at the interphase between MDS and MPN. To this end, further research is needed to find MDS/MPN defining characteristics that can be objectively quantified and measured. It is tempting to hypothesize that recurrent gene mutations or, more likely, combinations of mutations may serve this purpose but further study is need. This is especially true in acml and MDS/MPN-U because whereas monocytosis allows for the recognition of CMML and JMML, the differentiation between acml and MDS/MPN-U from MPNs is more difficult. 33 Disease-specific advances in the diagnostication of CMML have been reported. One key challenge for the diagnosis of CMML is discerning clonal from reactive monocytosis. This is important because the WHO diagnostic criterion of CMML does not require dysplasia, but can be diagnosed based solely on a persistent monocytosis that is unlikely to be caused by a concomitant condition. Because cytogenetic abnormalities occur in only 30% of cases, diagnosis is often delayed to ensure that monocytosis is persistent and expensive broad spectrum testing is often done to rule out concomitant conditions. 13 However, recent data has demonstrated that sequencing only nine genes in the bone marrow or peripheral blood of CMML is sufficient to identify a clonal mark in 93% of cases. 6 Given the increasing availability of targeted next generation sequencing myeloid panels that include these genes, our practice is to perform this test in the context of any suspected CMML case with diagnostic uncertainty. Another key challenge is to differentiate CMML from other myeloid neoplasms with monocytosis. To this end, investigators have identified a monocyte subset restriction in CMML not seen in reactive monocytosis, other myeloid neoplasms with monocytosis, or aged-matched controls. This repartitioning of monocytes was validated using an external validation cohort and performed with high sensitivity and specificity for the diagnosis of CMML. 34 Given that identifying this monocyte skewing is based on flow cytometry, translating this test to the clinical should be feasible and potentially incorporated in the diagnosis of this disease. Prognostication updates for adult MDS/MPNs Outside of RARS-T, the general prognosis of MDS/MPNs is poor. The median survival of CMML is reported to be 34 months and that of acml is reported to be approximately 1 year. 13 Although it is likely that significant heterogeneity exists among all adult MDS/ MPNs, their rarity (acml) and diagnostic uncertainty (MDS/ MPN-U) has minimized efforts for risk stratification in some MDS/MPNs. However, significant efforts have been recently made in CMML and RARS-T. The prognostication of CMML has been extensively investigated. At least 7 clinical models and 2 additional genetic models have been generated that incorporate ASXL1 mutation for the prognosis of CMML Although these efforts have provided a rich resource for risk stratification, the number of models available has led to a lack of consensus among clinicians and researchers for the definition of lower and higher risk CMML. Further, the validity and Hematology
4 relative prognostic power of these models had never been investigated in a large cohort precluding the rationale identification of a consensus model. To address this, we generated an international CMML database comprising 1800 cases for the purpose of identifying a consensus risk stratification model in CMML. Using this resource, we performed a detailed statistical analysis that was able to validate all models but were unable to identify a consensus model that was statistically superior. In fact, even after generating a novel model, we were unable to improve on the modest prognostic power of existing models. We next moved to interrogating the prognostic significance of gene mutation information and were able to confirm the independent prognostic significance of ASXL1 and identified CBL as independently prognostic in CMML. 13 Efforts are now underway to add these gene mutations to existing clinical models so that a consensus prognostic score can be devised for CMML. Although clinical anecdotes and small case series suggested that the natural history of RARS-T is relatively indolent relative to other MDS/MPNs, emerging data suggests that annotation of mutations in RARS-T may reveal a more aggressive subtype. A recent report identified SF3B1 and JAK2 mutations as favorably prognostic and associated with improved survival compared with their mutated counterpart. For example, SF3B1 wild-type cases of RARS-T had a median survival of 3.3 years compared to 6.9 years in mutated cases. 10 Therapies in adult MDS/MPNs There are no pharmacologic agents that have been demonstrated to alter the natural history of MDS/MPNs. As such, the general approach for the treatment of these diseases is to focus on therapeutic strategies tailored to individual patient symptomatologies. There is little evidence to suggest that asymptomatic MDS/ MPN patients benefit from current standard treatment but it is strongly recommended that all MDS/MPN cases be considered for clinical trial when available. Allogeneic stem cell transplant has the most robust data suggesting a disease modify effect in MDS/MPNs and should therefore be considered in higher-risk MDS/MPN cases Although there has been significant progress in the prognostication of CMML cases, challenges remain in adequately risk stratifying other MDS/MPNs for clinical transplant decision making. 35,40,46 Below is a summary of treatment options and there disease specific supporting data. Hypomethylating agents (HMAs) and noncytoreductive therapy Robust data exists demonstrating the activity of HMAs in CMML. Several phase II studies have demonstrated that azacitadine is active in CMML and associated with acceptable therapy-associated toxicity. 47 Decitabine has also been examined in multiple phase II trials, with response rates ranging from 10%-58% in patients with CMML. 48 Advances have also been made that allow for improved prediction of response to decitabine in an individual CMML patient. A methylation signature was recently identified that can predict CMML overall response with high accuracy. This signature incorporated differentially methylated regions at nonpromoter sites and was validated in an external cohort However, despite well documented activity, there exists no evidence that HMAs increase overall survival or decrease progression to AML. It is therefore our practice to reserve this therapy for CMML cases for which cytopenias are the predominant symptom. Very limited data is available for the use of HMAs for the treatment of acml, MDS/MPN-U, or RARS-T. There is also limited data testing the activity of lenalidomide in RARS-T. Three case reports have demonstrated significant activity with respect to hematologic and splenomegaly improvement irrespective of cytogenetic abnormalities Interferon has been tested in acml in limited number of cases with modest activity. 54,55 Cytoreductive agents MDS/MPN cases with rapid and severe myeloproliferative or constitutional symptoms should be considered for treatment with cytoreductive agents. Several studies have reported the efficacy of the topoisomerase inhibitors topotecan and etoposide both as single-agent and in combination with cytarabine Other trials have examined combination with arsenic or all-trans retinoic acid (ATRA) with modest results. 59,60 The only randomized study that has been performed in CMML randomized 105 patients with CMML to receive hydroxyurea or etoposide which favored the hydrea arm. 58 Induction chemotherapy has been used in CMML based on extrapolation from MDS. In our practice, we recommend induction chemotherapy in those cases with extreme or symptomatic leukocytosis, massive splenomegaly, or severe constitutional symptoms that are refractory to hydrea or other less intensive approaches. Conclusions and opportunities The MDS/MPNs are a unique class of myeloid malignancies that are coupled by a paradox in the bone marrow resulting in myeloid subset proliferation and bone marrow failure. Although the exact molecular convergence point is unknown, significant advances have been made secondary to a growing international community of MDS/MPN research. Although not fully annotated, the known spectrum of recurrent mutations in MDS/MONs have led to murine models that phenocopy MDS/MPNs and serve as useful tools for the molecular dissection of these diseases. Further, this genetic information has begun to augment our diagnosis and prognosis. It is anticipated that this information will additionally inform future therapeutic targets. Although there are therapeutic options that have the potential to improve the symptomatology of MDS/MPN patients, the current landscape of pharmacologics is limited. Ongoing studies testing JAK2 inhibitors in acml and CMML hold promise 61 (NCT and NCT ), but only a small number of studies are currently addressing MDS/MPN cases specifically. Other strategies that may benefit the therapeutic armamentarium in MDS/MPNs are mutation-specific. For instance, trials using PI3K and MEK inhibitors are being tested in RAS mutated myeloid malignancies to include CMML. Taken together, MDS/MPNs are aggressive cancers that could, by any definition, be considered an area of unmet need in cancer research. Although they converge on a unique bone marrow phenotype, significant nonoverlaping characteristics exist that make it challenging to apply observations broadly across disease members. It is anticipated that disease specific study will be required to fully elucidate the underlying pathology of these malignancies but that scientific momentum, growing disease awareness, and advancing genomic tools will result in dramatic improvement in MDS/MPN clinical care. Correspondence Eric Padron, Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Magnolia Dr, Tampa, FL 33612; Phone: ; Fax: ; eric.padron@moffitt.org. 352 American Society of Hematology
5 References 1. Padron E, Komrokji R, List AF. The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol. 2014;12(3): Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5): Invernizzi R, Travaglino E, Benatti C, et al. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia. Eur J Haematol. 2006;76(6): Sakaguchi H, Okuno Y, Muramatsu H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 2013;45(8): Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2013;28(2): Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012; 120(15): Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367): Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19): Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15): Broseus J, Alpermann T, Wulfert M, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013;27(9): Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124(9): Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia. Blood. 2015;125(7): Padron E, Garcia-Manero G, Patnaik MM, et al. An international data set for the study of chronic myelomonocytic leukemia (CMML) validates modern prognostic scoring systems and demonstrates a critical need for novel prognostication strategies. Blood Cancer J. 2015;5: e Gotlib J, Maxson JE, George TI, Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 2013;122(10): Malcovati L, Cazzola M. Refractory anemia with ring sideroblasts. Best Pract Res Clin Haematol. 2013;26(4): Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22): Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1): Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011;118(17): Itzykson R, Kosmider O, Renneville A, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood. 2013;121(12): Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycombassociated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6): Abdel-Wahab O, Gao J, Adli M, et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med. 2013;210(12): Kim E, Ilagan JO, Liang Y, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27(5): Wang J, Liu Y, Li Z, et al. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. Blood. 2011;118(2): Sanada M, Suzuki T, Shih LY, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009; 460(7257): Goodwin CB, Li XJ, Mali RS, et al. PI3K p110delta uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. Blood. 2014;123(18): Chang T, Krisman K, Theobald EH, et al. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013;123(1): Fleischman AG, Maxson JE, Luty SB, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013;122(22): Yildirim E, Kirby JE, Brown DE, et al. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell. 2013;152(4): Klinakis A, Lobry C, Abdel-Wahab O, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011; 473(7346): Zimmer SN, Lemieux ME, Karia BP, et al. Mice heterozygous for CREB binding protein are hypersensitive to gamma-radiation and invariably develop myelodysplastic/myeloproliferative neoplasm. Exp Hematol. 2012;40(4): e Ramirez-Herrick AM, Mullican SE, Sheehan AM, Conneely OM. Reduced NR4A gene dosage leads to mixed myelodysplastic/ myeloproliferative neoplasms in mice. Blood. 2011;117(9): Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007;31(11): Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/ myeloproliferative neoplasms. Blood. 2014;123(17): Selimoglu-Buet D, Wagner-Ballon O, Saada V, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 2015;125(23): Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19): Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes. Blood. 2012;120(12): Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6): Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99(3): Wassie EA, Itzykson R, Lasho TL, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic French Consortium Study. Am J Hematol. 2014;89(12): Patnaik MM, Padron E, Laborde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27(7): Kantarjian H, O Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008; 113(6): Park S, Labopin M, Yakoub-Agha I, et al. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Eur J Haematol. 2013;90(5): Onida F, Barosi G, Leone G, et al. Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. Haematologica. 2013;98(9): Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients Hematology
6 with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31(21): Cheng H, Kirtani VG, Gergis U. Current status of allogeneic HST for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2012; 47(4): Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15): Costa R, Abdulhaq H, Haq B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 2011;117(12): Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011;118(14): Meldi K, Qin T, Buchi F, et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest. 2015;125(5): Jeromin S, Haferlach T, Weissmann S, et al. Refractory anemia with ring sideroblasts and marked thrombocytosis (RARS-T) cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. Haematologica. 2014;100(4):e Huls G, Mulder AB, Rosati S, van de Loosdrecht AA, Vellenga E, de Wolf JT. Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. Blood. 2010;116(2): Taylor G, Culligan D, Vickers MA. Refractory anemia with ring sideroblasts associated with marked thrombocytosis complicated by massive splenomegaly treated with lenalidomide resulting in resolution of splenomegaly but severe and prolonged pancytopenia. Case Rep Hematol. 2013;2013: Ziarkiewicz M, Dwilewicz-Trojaczek J, Pastwinska A, et al. Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome. Pol J Pathol. 2010;61(2): Zhang X, Pan J, Guo J. Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon alpha-2b. Acta Haematol. 2013;130(1): Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007;110(9): Weihrauch MR, Staib P, Seiberlich B, Hoffmann M, Diehl V, Tesch H. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia. Leuk Lymphoma. 2004;45(4): Beran M, Estey E, O Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999;17(9): Wattel E, Guerci A, Hecquet B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood. 1996;88(7): Cambier N, Wattel E, Menot ML, Guerci A, Chomienne C, Fenaux P. All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study. Leukemia. 1996;10(7): Bejanyan N, Tiu RV, Raza A, et al. A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer. 2012;118(16): Padron E, Painter JS, Kunigal S, et al. GM-CSF-dependent pstat5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013;121(25): American Society of Hematology
Chronic myelomonocytic leukemia. Lymphoma Tumor Board. May 26, 2017
Chronic myelomonocytic leukemia Lymphoma Tumor Board May 26, 2017 Myeloproliferative Neoplasms CMML has an estimated incidence of less than 1 per 100,000 persons per year Myeloproliferative neoplasms (MPN)
More informationSUPPLEMENTARY INFORMATION
Supplementary Information S1 Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. Disease Patient population Frequency (%) Associated Clinical Characteristics
More informationPathogenesis and management of CMML
Pathogenesis and management of CMML Raphaël Itzykson, Hôpital Saint-Louis, Paris International Conference of the Korean Society of Hematology March 29th 2018 대한혈액학회 Korean Society of Hematology COI disclosure
More informationBlast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome
RESEARCH ARTICLE Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome AJH Mrinal M. Patnaik, 1 Emnet A. Wassie, 1 Terra L. Lasho, 2 Curtis
More informationMolecular profiling in confirming the diagnosis of early myelodysplastic syndrome
Molecular profiling of early MDS Hematopathology - March 2016 Article Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome Maya Thangavelu 1,*, Ryan Olson 2, Li Li 2, Wanlong
More informationCase Presentation. Attilio Orazi, MD
Case Presentation Attilio Orazi, MD Weill Cornell Medical College/ NYP Hospital Department of Pathology and Laboratory Medicine New York, NY United States History 60 year old man presented with anemia
More informationMyelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Updated
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Updated Attilio Orazi, MD, FRCPath. (Engl.) Professor of Pathology and Laboratory Medicine Weill Cornell Medical College/NYP Hospital New York, NY
More informationOpportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD
Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2
More informationSH A CASE OF PERSISTANT NEUTROPHILIA: BCR-ABL
SH2017-0124 A CASE OF PERSISTANT NEUTROPHILIA: BCR-ABL NEGATIVE John R Goodlad 1, Pedro Martin-Cabrera 2, Catherine Cargo 2 1. Department of Pathology, NHS Greater Glasgow & Clyde, QEUH, Glasgow 2. Haematological
More informationChronic Myelomonocytic Leukemia with molecular abnormalities SH
Chronic Myelomonocytic Leukemia with molecular abnormalities SH2017-0351 Madhu P. Menon MD,PhD, Juan Gomez MD, Kedar V. Inamdar MD,PhD and Kristin Karner MD Madhu P Menon, MD, PhD Henry Ford Hospital Patient
More informationTET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia
Short Report TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia Yajuan Cui 1,2 *, Hongyan Tong 3 *, Xin Du 4 *, Bing
More informationMDS/MPN: What it is and How it Should be Treated?
MDS/MPN: What it is and How it Should be Treated? MDS MPN Rachel Salit, MD Assistant Member Fred Hutchinson Cancer Research Center rsalit@fredhutch.org MDS Founda>on Pa>ent & Family Forum: May 20, 2017
More informationJuvenile Myelomonocytic Leukemia (JMML)
Juvenile Myelomonocytic Leukemia (JMML) JMML: Definition Monoclonal hematopoietic disorder of childhood characterized by proliferation of the granulocytic and monocytic lineages Erythroid and megakaryocytic
More informationWHO Update to Myeloproliferative Neoplasms
WHO Update to Myeloproliferative Neoplasms Archana M Agarwal, MD, Associate Professor of Pathology University of Utah Department of Pathology/ARUP Laboratories Myeloproliferative Neoplasms The categories
More informationMutational Impact on Diagnostic and Prognostic Evaluation of MDS
Mutational Impact on Diagnostic and Prognostic Evaluation of MDS Elsa Bernard, PhD Papaemmanuil Lab, Computational Oncology, MSKCC MDS Foundation ASH 2018 Symposium Disclosure Research funds provided by
More informationNovità nelle MDS. Matteo G Della Porta. Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy
Novità nelle MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu Outline ARCH Predictive value of somatic
More informationMyelodysplastic syndromes and the new WHO 2016 classification
Myelodysplastic syndromes and the new WHO 2016 classification 32nd General Annual Meeting of the Belgian Hematology Society 10-11 February 2017 Gregor Verhoef, Departement of Hematology, University Hospital
More informationMyelodysplastic syndromes: revised WHO classification and distinction from non-neoplastic conditions
Myelodysplastic syndromes: revised WHO classification and distinction from non-neoplastic conditions Robert P Hasserjian, MD Associate Professor Massachusetts General Hospital and Harvard Medical School
More informationNOVEL APPROACHES IN THE CLASSIFICATION AND RISK ASSESSMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES-CLINICAL IMPLICATION
ORIGINAL ARTICLES NOVEL APPROACHES IN THE CLASSIFICATION AND RISK ASSESSMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES-CLINICAL IMPLICATION Ilina Micheva 1, Rosen Rachev 1, Hinco Varbanov 1, Vladimir
More informationMyeloproliferative Neoplasms
Myeloproliferative Neoplasms (MPN and MDS/MPN) Attilio Orazi, MD, FRCPath Weill Cornell Medical College/ NY Presbyterian Hospital, New York, NY USA EAHP EDUCATIONAL SESSION: Updated WHO classification
More informationDISCLOSURE Luca Malcovati, MD. No financial relationships to disclose
ICUS, CCUS and CHIP Luca Malcovati, MD Department of Molecular Medicine, University of Pavia Medical School, & Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy DISCLOSURE
More informationNews Release. Title Integrated molecular profiling of juvenile myelomonocytic leukemia
News Release Title Integrated molecular profiling of juvenile myelomonocytic leukemia Key Points We identified ALK/ROS1 tyrosine kinase fusions (DCTN1-ALK, RANBP2-ALK, and TBL1XR1-ROS1) in patients with
More informationMyelodysplastic syndromes
Myelodysplastic syndromes Robert P Hasserjian Massachusetts General Hospital, Boston, MA Disclosure of Relevant Financial Relationships Dr. Hasserjian declares he has no conflict(s) of interest to disclose.
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationTreatment of low risk MDS
Treatment of low risk MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu International Prognostic Scoring
More informationPoor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia
Original Article Diagnostic Hematology Ann Lab Med 2018;38:495-502 https://doi.org/10.3343/alm.2018.38.6.495 ISSN 2234-3806 eissn 2234-3814 Poor Prognostic Implication of ASXL1 Mutations in Korean Patients
More informationMyelodysplastic syndrome is a highly heterogeneous hematopoietic
SHORT COMMUNICATION Clinical Characteristics and Prognosis of 48 Patients with Mutations in Myelodysplastic Syndrome Yulu Tian #, Ruijuan Zhang #, Linhua Yang* Yang L. Clinical Characteristics and Prognosis
More informationPublished Ahead of Print on April 14, 2016, as doi: /haematol Copyright 2016 Ferrata Storti Foundation.
Published Ahead of Print on April 14, 2016, as doi:10.3324/haematol.2016.143214. Copyright 2016 Ferrata Storti Foundation. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse
More informationMyelodysplastic/myeloproliferative neoplasms. Department of Pathology, Oregon Health & Science University, Portland OR USA;
Atlas of Genetics and in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Leukaemia Section Review Philipp W. Raess Department of, Oregon Health & Science University, Portland OR USA; raess@ohsu.edu
More informationEditorial Process: Submission:11/21/2017 Acceptance:06/19/2018
DOI:10.22034/APJCP.2018.19.7.1825 RESEARCH ARTICLE Editorial Process: Submission:11/21/2017 Acceptance:06/19/2018 The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome Punchita
More informationLeukemia and subsequent solid tumors among patients with myeloproliferative neoplasms
Leukemia and subsequent solid tumors among patients with myeloproliferative neoplasms Tiziano Barbui (tbarbui@asst-pg23.it Hematology and Research Foundation,Ospedale Papa Giovanni XXIII, Bergamo Italy
More informationAPPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE
APPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE Rashmi Kanagal-Shamanna, MD Assistant Professor Hematopathology & Molecular Diagnostics Department of Hematopathology The University
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationShould Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!!
Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!! Lindsay Anne Magura Rein, MD Division of Hematologic Malignancies and Cellular Therapy/BMT A Little Bit of History.. 1665 Advanced
More informationUpdate on Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Kaaren Reichard Mayo Clinic Rochester
Update on Myelodysplastic Syndromes and Myeloproliferative Neoplasms Kaaren Reichard Mayo Clinic Rochester Reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Learning Objectives Present
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationClinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
Cancer Biol Med 2016. doi: 10.20892/j.issn.2095-3941.2016.0043 REVIEW Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes Joseph A. Clara 1, David A. Sallman 2,
More informationMyelodysplastic syndrome (MDS) & Myeloproliferative neoplasms
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)
More informationFerrata Storti Foundation
GUIDELINE ARTICLE An International MDS/MPN Working Group s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
More informationChanges to the 2016 WHO Classification for the Diagnosis of MDS
Changes to the 2016 WHO Classification for the Diagnosis of MDS Welcome to Managing MDS. I am Dr. Ulrich Germing, and today, I will provide highlights from the 14th International Symposium on MDS in Valencia,
More informationShould lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France
Should lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France Myelodysplastic syndromes (MDS) are heterogeneous disorders that range from conditions with a
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationMyelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management
Received: 2 October 2017 Accepted: 2 October 2017 DOI: 10.1002/ajh.24930 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and
More informationPrognostic models in myelodysplastic syndromes
MYELODYSPLASTIC SYNDROMES:WHAT MAKES THERAPY EFFECTIVE? Prognostic models in myelodysplastic syndromes Rafael Bejar 1 1 Moores Cancer Center, Division of Hematology and Oncology, University of California,
More informationMyelodysplastic Syndromes: Everyday Challenges and Pitfalls
Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Kathryn Foucar, MD kfoucar@salud.unm.edu Henry Moon lecture May 2007 Outline Definition Conceptual overview; pathophysiologic mechanisms Incidence,
More informationHematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationMyelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression
Myelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression Carlos E. Bueso-Ramos, M.D., Ph.D Department of Hematopathology The University of Texas M.
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationIntro alla patologia. Giovanni Barosi. Fondazione IRCCS Policlinico San Matteo Pavia
Settima Giornata Fiorentina dedicata ai pazienti con malattie mieloproliferative croniche Sabato 13 Maggio 2017 CRIMM Centro di Ricerca e Innovazione per le Malattie Mieloproliferative AOU Careggi Intro
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationMYELODYSPLASTIC SYNDROMES: A diagnosis often missed
MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic
More informationACCME/Disclosures. History. Hematopathology Specialty Conference Case #4 4/13/2016
Hematopathology Specialty Conference Case #4 Sherrie L. Perkins MD, PhD University of Utah ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose
More informationManagement of Myelodysplastic Syndromes
Management of Myelodysplastic Syndromes Peter L. Greenberg, MD Stanford Cancer Institute Myelodysplastic Syndromes: Clinical & Molecular Advances for Disease Classification and Prognostication MDSs: A
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More information74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow
74y old Female with chronic elevation of Platelet count August 18, 2005 Faizi Ali, MD Hematopathology Fellow Clinical History Patient is a 74y old otherwise healthy Caucasian female with no major complaint
More informationApproaching myeloid neoplasms: diagnostic algorithms
Approaching myeloid neoplasms: diagnostic algorithms Alexandar Tzankov Histopathology Pathology Content Integration of clinical and laboratory data Bone marrow evaluation approaching Myeloproliferative
More informationLay Summaries ASH 2017
Lay Summaries ASH 2017 Purpose of Document: This document contains a collection of lay summaries of accepted ASH 2017 abstracts from the following investigators: MDS CRC Members/Affiliates, Fellows (past
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationNew treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke
University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version
More informationJuvenile and Chronic Myelo-Monocytic Leukemia
Juvenile and Chronic Myelo-Monocytic Leukemia Haematopoietic stem cell Lympho-myeloid progenitor cell MEP CFU-GM lymphoid progenitor cell BFU-E CFU-MK CFU-E erythro CFU-M CFU-G CFU-T CFU-B MGK red blood
More informationLaboratory Service Report
Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-ih2xuglwpq.ashx Indication for Test DS CR Pathogenic utations Detected CR 1. JAK2: c.1849g>t;p.val617phe
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More information9/25/2017. Disclosure. I have nothing to disclose. Young S. Kim MD Dept. of Pathology
Disclosure MAST CELLNEOPLASM I have nothing to disclose. Young S. Kim MD Dept. of Pathology 1 Objectives What is mast cell lineage? Changes in updated WHO 2016 mastocytosis Issues of Mastocytosis CD30
More informationASBMT MDS/MPN Update Sunil Abhyankar, MD
ASBMT MDS/MPN Update Sunil Abhyankar, MD Professor of Medicine Medical Director, Pheresis and Cell Processing Division of Hematologic Malignancies and Cellular Therapeutics Department of Internal Medicine
More informationSupplemental Material. The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia
Supplemental Material The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia Torsten Haferlach, 1 Anna Stengel, 1 Sandra Eckstein, 1 Karolína
More informationExamining Genetics and Genomics of Acute Myeloid Leukemia in 2017
Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction
More informationSeptember 20, Submitted electronically to: Cc: To Whom It May Concern:
History Study (NOT-HL-12-147), p. 1 September 20, 2012 Re: Request for Information (RFI): Building a National Resource to Study Myelodysplastic Syndromes (MDS) The MDS Cohort Natural History Study (NOT-HL-12-147).
More informationWHO 2016/17 update on Myeloproliferative Neoplasms. Anna Ruskova Auckland City Hospital New Zealand
WHO 2016/17 update on Myeloproliferative Neoplasms Anna Ruskova Auckland City Hospital New Zealand BLOOD, 19 MAY 2016 x VOLUME 127, NUMBER 20 2 2016/17 Classification of Myeloproliferative Neoplasms Chronic
More informationCharacterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases
Article Characterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases Keming Lin 1,*, Gang Xu 1, Jie-Gen Jiang 1, Mayuko Imai 1, Zhao Wu 1, Paris Petersen 1, Kim Janatpour 1, and Bashar
More informationHENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Part 4 MYELOID NEOPLASMS
HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD Part 4 MYELOID NEOPLASMS Introduction: o Myeloid neoplasms are divided into three major categories: o Acute
More informationIntegrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University
Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationMyelodysplastic syndromes Impact of Biology. Lionel Adès Hopital Saint Louis Groupe Francophone des SMD. Épidémiologie
Myelodysplastic syndromes Impact of Biology Lionel Adès Hopital Saint Louis Groupe Francophone des SMD Épidémiologie Incidence : 3 à 6 / 100 000 hab. / An Prédomine chez les sujets âgés Augmentation de
More informationDisclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms
Myeloproliferative Neoplasms: A Case-Based Approach Disclosures No conflicts of interests regarding the topic being presented Adam M. Miller, MD PGY-4 Resident Physician Department of Pathology and Laboratory
More informationWhat is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification
What is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification Rami Komrokji, MD Clinical Director Malignant Hematology Moffitt Cancer Center Normal Blood and Bone Marrow What is MDS Myelodysplastic
More informationBeyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure
Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for
More informationThe Changing Face of MDS: Advances in Treatment
Thank you very much again for listening to me. We are going to be talking now in terms of therapy of MDS or The Changing Face of MDS Advances in Treatment. My name is Guillermo Garcia-Manero. I am a Professor
More information[COMPREHENSIVE GENETIC ASSAY PANEL ON
2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for
More informationMyelodysplastic syndromes in adults aged less than 50 years: Incidence and clinicopathological data
JBUON 2014; 19(4): 999-1005 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Myelodysplastic syndromes in adults aged less than 50 years: Incidence
More informationLet s Look at Our Blood
Let s Look at Our Blood Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC 10,000,000,000 WBCs/day Bone Marrow: The Blood
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More informationMyeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
More informationPublished Ahead of Print on June 22, 2017, as doi: /haematol Copyright 2017 Ferrata Storti Foundation.
Published Ahead of Print on June 22, 2017, as doi:10.3324/haematol.2017.166173. Copyright 2017 Ferrata Storti Foundation. Molecular analysis of myelodysplastic syndrome with isolated del(5q) reveals a
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationSession 4: Summary and Conclusions
Session 4: Summary and Conclusions Total cases in Session 4 Myeloproliferative neoplasms 16 cases Oral #300 (CEL, NOS) Mastocytosis 2 cases Oral #156 (SM-AHN) Myeloid/lymphoid neoplasms with eosinophilia
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationEtiology. Definition MYELODYSPLASTIC SYNDROMES. De novo. Secondary MDS (10 years earlier than primary) transformation
MYELODYSPLASTIC SYNDROMES Rashmi Kanagal-Shamanna, MD Assistant Professor Hematopathology & Molecular Diagnostics The University of Texas M.D. Anderson Cancer Center Houston, Texas No relevant COIs to
More informationA prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes.
Protocol Synopsis Study Title A prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes. Short Title European MDS
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationMPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs
MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs Hans Michael Kvasnicka University of Frankfurt, Germany hans-michael.kvasnicka@kgu.de Disclosure of
More informationSESSION 1 Reactive cytopenia and dysplasia
SESSION 1 Reactive cytopenia and dysplasia Falko Fend, Tübingen & Alexandar Tzankov, Basel 1 Disclosure of speaker s interests (Potential) conflict of interest none Potentially relevant company relationships
More informationCBL and EZH2 as new molecular markers in MPN
CBL and EZH2 as new molecular markers in MPN Andy Chase University of Southampton and Wessex Regional Genetics Laboratory Salisbury, UK Munich 2011 * Myeloproliferative neoplasms MDS/MPN Myelodysplastic
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationUnderstanding & Treating Myelodysplastic Syndrome (MDS)
Understanding & Treating Myelodysplastic Syndrome (MDS) Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC Let s Look at Our
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationMolecular techniques in a case of concurrent BCR-ABL1 positive CML and CMML
reprinted from november 2014 pathology laboratory medicine laboratory management Molecular techniques in a case of concurrent BCR-ABL1 positive CML and CMML CAP TODAY and the Association for Molecular
More informationOverview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
Int J Hematol (2008) 88:24 29 DOI 10.1007/s12185-008-0118-z PROGRESS IN HEMATOLOGY Transfusional iron overload and iron chelation therapy Overview of guidelines on iron chelation therapy in patients with
More information